Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials-Reference-Cited by-同舟云学术

Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials

Published:2021-04-03 Issue:2 Volume:26 Page:103-129
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Kaur Jasmeet¹^ORCID,Singh Paramveer²,Enzler Thomas³,Sahai Vaibhav³^ORCID

Affiliation:

1. Department of Internal Medicine, Saint Joseph Mercy Oakland Hospital, Pontiac, MI, USA

2. Division of Hematology and Oncology, Department of Internal Medicine, Wayne State University, Detroit, MI, USA

3. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2021.1905795

Reference189 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

3. SEER Cancer Statistics Review, 1975–2017, National cancer institute. [Internet]. SEER web site. [cited 2020 December 9]. Available from: https://seer.cancer.gov/csr/1975_2017/.

4. Early detection of pancreatic cancer

5. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty;Expert Review of Anticancer Therapy;2021-11-23

2. Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma;Annals of Gastroenterological Surgery;2021-09-29